Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, pha...

Article Oncology

Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines

David S. Ettinger et al.

Summary: The NCCN Guidelines for NSCLC cover all aspects of management, with recent updates focusing on targeted therapies, immunotherapies, and their respective biomarkers.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Article Oncology

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Jacqueline V. Aredo et al.

Summary: Consolidation durvalumab did not benefit patients with EGFR-mutated unresectable stage III NSCLC and was associated with a high frequency of immune related adverse events. Patients who switched to osimertinib after durvalumab treatment may be more susceptible to incident adverse events. Further investigation is needed for concurrent CRT with induction or consolidation EGFR TKIs as definitive treatment.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China

Dawei Zhu et al.

Summary: This study analyzed the prevalence of comorbidities among lung cancer patients in China and found that comorbidities are positively associated with increased risk of hospital readmission and in-hospital death.

BMC CANCER (2021)

添加到收藏夹

Article Oncology

GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy

Pierre-Benoit Ancey et al.

Summary: The study highlights the importance of GLUT1 in tumor-associated neutrophils (TAN) within lung tumors, with increased glucose uptake mediated by GLUT1 impacting tumor growth and radiotherapy resistance. Targeting metabolic vulnerabilities to support anti-tumor neutrophils may be a promising strategy for cancer treatment.

CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere et al.

Summary: KRAS inhibition can reverse an immunosuppressive tumor microenvironment and sensitize tumors to checkpoint inhibitor therapy (CIT) through multiple mechanisms.

MOLECULAR CANCER THERAPEUTICS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity

Guang Lei et al.

Summary: The study reveals the critical role of ferroptosis in p53-mediated tumor radiosensitivity, promoting lipid peroxidation and cell death by inhibiting SLC7A11. P53 deficiency leads to radioresistance in cancer cells or tumors, while ferroptosis inducers that inhibit SLC7A11 significantly enhance tumor sensitivity to radiotherapy.

ONCOGENE (2021)

添加到收藏夹

Article Oncology

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial

Jie Wang et al.

Summary: This study showed that tislelizumab combined with chemotherapy can significantly improve progression-free survival in patients with advanced squamous non-small-cell lung cancer, providing potential benefits in clinical practice.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski et al.

Summary: The final analysis of IMpower150 study showed a numerical OS improvement with ACP compared to BCP in metastatic nonsquamous NSCLC patients, while ABCP demonstrated continued OS improvement in all patients.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Caicun Zhou et al.

Summary: A randomized, double-blind, phase 3 study found that Sintilimab plus GP showed better progression-free survival compared to GP alone in first-line treatment for patients with locally advanced or metastatic sqNSCLC. The toxicity of the treatment was acceptable, and no new unexpected safety signals were observed.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Cell Biology

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Amaia Martinez-Usatorre et al.

Summary: In the treatment of nonsmall cell lung cancer, antiangiogenic therapy can slow tumor progression, but unlike in other cancers, the addition of PD-1 or PD-L1 antibodies does not provide benefits. Antiangiogenic treatment facilitates tumor infiltration by PD-1(+) T-regs, but targeting both tumor-associated macrophages types can improve treatment efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response

Meagan Montesion et al.

Summary: The study uncovers the pan-cancer landscape of HLA-I LOH, showing an unexpected relationship between HLA-I LOH and TMB, and demonstrating HLA-I LOH as a significant negative predictor of outcomes after ICI treatment. These findings inform a combined predictor of outcomes after ICI and have implications for tumor vaccine development.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K. Park et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer

John Conibear

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Meeting Abstract Oncology

GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

C. Zhou et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy

Qing Zhou et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Meeting Abstract Oncology

PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

J. Vansteenkiste et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

Kari Chansky et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. E. Postmus et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Critical Care Medicine

The Eighth Edition Lung Cancer Stage Classification

Frank C. Detterbeck et al.

CHEST (2017)

添加到收藏夹

Article Medicine, General & Internal

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlesi et al.

LANCET (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Oncology

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

Walter J. Curran et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)

添加到收藏夹

Review Oncology

Is Concurrent Chemoradiation the Standard of Care for Locally Advanced Non-small Cell Lung Cancer? A Review of Guidelines and Evidence

N. O'Rourke et al.

CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Oncology

Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer

Anne Auperin et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Medicine, General & Internal

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.

Rafael Rosell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

相关参考文献

Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China

GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer

GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The Eighth Edition Lung Cancer Stage Classification

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

Is Concurrent Chemoradiation the Standard of Care for Locally Advanced Non-small Cell Lung Cancer? A Review of Guidelines and Evidence

Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

相关参考文献

导出引文

分享论文